About D(1A) dopamine receptor
D(1A) dopamine receptor (DRD1) is a protein
from Homo sapiens identified by UniProt accession
P21728, 446 residues long.
MolForge cross-references it against 0 known binders and
303 disease associations.
Target properties
| Protein name | D(1A) dopamine receptor |
| UniProt accession | P21728 |
| Gene | DRD1 |
| Organism | Homo sapiens |
| Length | 446 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (303)
Diseases linked to this target (Open Targets).
- hemorrhage · score 0.60
- Parkinson disease · score 0.59
- cardiovascular disease · score 0.54
- unipolar depression · score 0.54
- schizophrenia · score 0.51
- Tourette syndrome · score 0.48
- hypertension · score 0.47
- neurodegenerative disease · score 0.46
- coronary artery disease · score 0.46
- kidney failure · score 0.43
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21728-F1 | alphafold | PREDICTED | 72.46 | — |
Amino-acid sequence (446 residues)
MRTLNTSAMD GTGLVVERDF SVRILTACFL SLLILSTLLG NTLVCAAVIR FRHLRSKVTN FFVISLAVSD LLVAVLVMPW KAVAEIAGFW PFGSFCNIWV AFDIMCSTAS ILNLCVISVD RYWAISSPFR YERKMTPKAA FILISVAWTL SVLISFIPVQ LSWHKAKPTS PSDGNATSLA ETIDNCDSSL SRTYAISSSV ISFYIPVAIM IVTYTRIYRI AQKQIRRIAA LERAAVHAKN CQTTTGNGKP VECSQPESSF KMSFKRETKV LKTLSVIMGV FVCCWLPFFI LNCILPFCGS GETQPFCIDS NTFDVFVWFG WANSSLNPII YAFNADFRKA FSTLLGCYRL CPATNNAIET VSINNNGAAM FSSHHEPRGS ISKECNLVYL IPHAVGSSED LKKEEAAGIA RPLEKLSPAL SVILDYDTDV SLEKIQPITQ NGQHPT
Explore D(1A) dopamine receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets